Faraone SV, Childress A, Caras S, et al. - AR19 was identified as efficacious on all endpoints in the treatment of attention-deficit/hyperactivity disorder (ADHD) and was generally well tolerated.

• This randomized, double-blind, placebo-controlled, fixed-dose, forced titration, multicenter trial involved  320 participants.

• Participants were titrated to 20 mg or 40 mg AR19 daily or placebo.

• Compared with placebo, the least squares mean treatment differences were −7.2 (−11.3 to −3.1) and −7.3 (−11.4 to −3.2) for the AR19 20-mg group and the AR19 40-mg group, respectively.